Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib + anlotinib first-line treatment for EGFR exon 21 L858R-mutant advanced non-squamous NSCLC
ChiCTR2300072027Phase 4Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib and anlotinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Started May 2023; status: recruiting.
02
Drugs
furmonertinibanlotinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2300072027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072027.